GlassScriptPhysician profile
Adel Y Daas
NPI 1518049964
$3,119.28
in general payments reported to CMS, 2019-2025
16 companies · $39.78 in 2025
The $39.78 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,501 · 2020: $172 · 2021: $23.65 · 2022: $383 · 2025: $39.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apollo Endosurgery US INC | $1,347.65 | 2019 | |
| Pentax of America, INC. | $910.21 | 2019-2022 | |
| Abbvie INC. | $222.95 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.52 | 2019-2020 | |
| Olympus America INC. | $169.93 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.60 | 2019 | |
| Allergan, INC. | $47.91 | 2019 | |
| Qol Medical, LLC | $25.28 | 2025 | Sucraid |
| Boston Scientific Corporation | $24.18 | 2019 | |
| Merck Sharp & Dohme LLC | $20.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.90 | 2019 | |
| Smith+Nephew, INC. | $14.50 | 2025 | Stravix Pl |
| Cook Medical LLC | $13.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.83 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $9.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Daas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.